Elevated plasma levels of asymmetric dimethylarginine and the risk for arrhythmic death in ischemic and non-ischemic, dilated cardiomyopathy – A prospective, controlled long-term study

2020 ◽  
Vol 83 ◽  
pp. 37-42
Author(s):  
Achim Leo Burger ◽  
Stefan Stojkovic ◽  
André Diedrich ◽  
Svitlana Demyanets ◽  
Johann Wojta ◽  
...  
Keyword(s):  
Dilated Cardiomyopathy ◽  
Plasma Levels ◽  
Asymmetric Dimethylarginine ◽  
Elevated Plasma ◽  
Term Study ◽  
Arrhythmic Death ◽  
Long Term Study ◽  
Non Ischemic Dilated Cardiomyopathy

Sertraline efficacy in major depression: A long-term study with plasma levels

2002 ◽  
Vol 12 ◽  
pp. 189
Author(s):  
M.C. Mauri ◽  
M.E. Scalvini ◽  
G. Cerveri ◽  
L.S. Volonteri ◽  
F. Regispani ◽  
...  
Keyword(s):  
Major Depression ◽  
Plasma Levels ◽  
Term Study ◽  
Long Term Study

scholarly journals Clinical Efficacy of Valproic Acid in Relation to Plasma Levels

1978 ◽  
Vol 5 (4) ◽  
pp. 385-387 ◽  
Author(s):  
J. Bruni ◽  
B.J. Wilder ◽  
L.J. Willmore ◽  
H.J. Villarreal ◽  
M. Thomas ◽  
...  
Keyword(s):  
Optimal Control ◽  
Valproic Acid ◽  
Clinical Response ◽  
Plasma Levels ◽  
Seizure Control ◽  
The United States ◽  
Active Therapy ◽  
Term Study ◽  
Long Term Study

SUMMARY:Valproic acid is a new antiepileptic drug recently introduced in the United States for the treatment of absence seizures. In this study on patients with absence and other seizure types, the majority of patients achieved optimal control within four weeks of therapy. No patient responded to valproic acid who did not show an initial clinical response by four weeks of active therapy. Optimal response was generally achieved when plasma levels were greater than 55 μg/ml. Excellent clinical response was observed in the treatment of absence and myoclonic seizures. Twenty-two patients continued in a long term study have maintained the same degree of seizure control as observed at the time of optimal control.

A Month-by-Month Long-Term Study on Carbamazepine: Clinical, EEG and Pharmacological Evaluation

1979 ◽  
Vol 7 (2) ◽  
pp. 152-157 ◽  
Author(s):  
F Monaco ◽  
A Riccio ◽  
M Fantini ◽  
A Baruzzi ◽  
P L Morselli
Keyword(s):  
Side Effects ◽  
Plasma Levels ◽  
Partial Epilepsy ◽  
Term Study ◽  
Breakdown Rate ◽  
Long Term Study ◽  
First Choice ◽  
Epileptic Patients ◽  
Clinical Eeg

Carbamazepine plasma levels were monitored for a twelve-month period in twenty epileptic patients. Seizure frequency decreased remarkably on inclusion of the drug in the therapy and attainment of plasma levels of 7–9 μg/ml. A faster breakdown rate in children was confirmed, while carbamazepine-10, 11-epoxide was present for carbamazepine levels above 4–5 μg/ml. EEG tracings did not show substantial modifications; this variable was thus considered to be of little value in assessing the clinical picture. Side-effects were minimal. Carbamazepine is increasingly becoming the drug of first choice in the management of both generalized and partial epilepsy, while better and more rapid results are obtained in monotherapy.

Sign in / Sign up

Export Citation Format

Share Document